Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Secondary autoimmune and inflammatory diseases (sec.AIID) post allogeneic HSCT

Retrospective Studies

Complications Working Party (CWP)

Autoimmune Diseases Working Party (ADWP)

Type de traitement

Investigateur principal

Arsene Mekinian

Graft rejection in haploidentical HSCT: survey of subsequent therapeutic options

Closed Survey/Study

Complications Working Party (CWP)

Type de traitement

Allogeneic - Haploidentical

Investigateur principal

Nadira Durakovic

Machine Learning grading system for acute graft-versus host disease

Retrospective Studies

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Steroid refractory acute graft-versus-host disease - survey

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Central nervous system disorders following hematopoietic stem cell transplantation: a prospective observational study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP)

Non-interventional Prospective Studies

Complications: infectious

Complications: non-infectious

Infectious Diseases Working Party (IDWP)

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Martin Schmidt-Hieber

LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Retrospective Studies

Autoimmune Diseases Working Party (ADWP)

Complications Working Party (CWP)

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Kirill Kirgizov

Fecal transplant FOR GVHD

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Dr. J. Bilinski

Incidence and outcome of pregnancy following stem cell transplantation

Retrospective Studies

Complications: non-infectious

Complications Working Party (CWP)

Type de traitement

Investigateur principal

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Clinical Trials Phase I-III

Complications: infectious

Infectious Diseases Working Party (IDWP)

Complications Working Party (CWP)

Type de traitement

Investigateur principal